Gould Partners Updates Coverage on ChromaDex, Rates 'Strong Buy'

Gould Partners released a follow-up research report today on ChromaDex CDXC, providing further color on the company's insider shareholders. In the report, Gould Partners notes, "As the authority source for photochemical reference materials, ChromaDex has the benefit of understanding market demand for ingredients far before many of its end markets." The report later identifies two significant shareholders in the company and outlines their investment backgrounds. Gould Partners initiated coverage of ChromaDex at a Strong Buy rating on August 22, 2012. In its press releases, the firm has provided a link to a public PDF report for further information. The firm notes, "Much of ChromaDex's growth will come from monetizing its leading informational flow. The company already understands what ingredients are about to become popular and, based on that information, is then able to make relevant development decisions." Gould Partners rates ChromaDex at a Strong Buy rating from an analyst disclaiming compensation for research coverage. Recent headlines for ChromaDex include an announcement that the company's CEO will be speaking at the 2012 Gateway Conference on September 6, 2012. Another press release states that ChromaDex will release human clinical data on its patented compound, pterostilbene (pTeroPure), at an American Heart Association conference on September 20, 2012.